MRK
Another pipeline win
Merck is back with more good news for its pipeline, and this time it comes from tulisokibart — an investigational antibody aimed at TL1A. The company says the Phase 2b MK-7240-012 study in moderate to severe hidradenitis suppurativa hit both its primary and key secondary endpoints.
That’s pharma-speak for: the drug did what it was supposed to do, and then some. For a company like Merck, every clean readout matters because investors are constantly asking the same annoying-but-fair question: what’s next after Keytruda?
Why this matters
Hidradenitis suppurativa is a painful, chronic skin condition, so a drug that can move the needle there could open up a meaningful commercial lane if later-stage data hold up. Early wins don’t guarantee a blockbuster, but they do keep the market interested — and in biotech, attention is half the battle.
The bigger picture
Merck has been stacking up pipeline headlines lately, which is nice if you own the stock and mildly exhausting if you’re trying to keep up. The takeaway here is simple:
- the drug appears to be working in a difficult disease area
- the company gets another data point to support future development
- investors get one more reason to believe Merck’s pipeline isn’t just a Keytruda echo chamber
Big picture: this is the kind of update that won’t rewrite Merck’s story overnight, but it absolutely helps the company’s “we’ve got more than one trick up our sleeve” pitch.